

Inserm Transfert (France) and Translational Research Informatics Center (Japan) enter into international cooperation agreement regarding translational researches

Paris, (France), Kobe (Japan), May 7, 2014 - Inserm Transfert, the private subsidiary of the French National Institute of the Health and Medical Research (Inserm), and Translational Research Informatics Center (TRI), in the name of Foundation for Biomedical Research and Innovation (FBRI), committed to promote academic translational researches in Japan, announce today an international cooperation agreement to introduce French biomedical-related patents to the Japanese market.

Such collaboration will be developed through translational activities which leads to the results from the basic research to the clinical practice and focus on the promotion of the potential license agreements with companies from the Japanese life science industry.

This international alliance marks a significant milestone in strengthening relationships between Inserm Transfert and TRI, two structures from Academia with a prime mission of transferring to the industry for the patients sake. Both stakeholders share the same vision that a comprehensive worldwide eco-system in translational research in the field of biomedical research, is the best way to accelerate the path from scientific achievements to patients.

Each partner brings unique strengths to the collaboration: TRI's expertise in the support of innovation of medical technologies and data center and statistical center management, by facilitating the transfer of medical research findings or inventions to clinical practice will be seamlessly coupled with Inserm Transfert know-how to source innovative inventions from the Inserm laboratories, to set-up collaboration schemes with industrials, and to present a large range of licensing opportunities.

Complementing each other, the mutual interactions offer opportunities to foster biomedical inventions in the Japanese market and develop them at an international level.

Augustin Godard, EVP Open Innovation of Inserm Transfert confirms: "We share the same goal of building sustainable structures for the benefit of the whole innovation ecosystem as well as a very strong hybrid academic-industrial DNA. It is our belief that the cooperation with TRI, with its experiences in total supports for the management of clinical trials and its embedded knowledge in the Japanese scientific, translational and industrial community, will constitute a giant leap in the international reach of French biomedical inventions, in the service of both patients and Science."

Professor Masanori Fukushima, Director and Chairman of TRI comments: "Inserm is one of the worldwide leading institutions in the field of Health research. It is a great pleasure to have such a relationship with Inserm Transfert, which is in charge of the technology transfer and

licensing of Inserm patents, and be able to introduce inventions of Inserm to Japanese universities and pharmaceutical companies. We believe that our relationship contributes to accelerate translational research in Japan. TRI and Inserm Transfert are looking forward to further the collaboration in the future so that the Japanese academia oriented patents can be introduced worldwide. This must lead the inventions arising from Japanese academia to the global exposure."

About Inserm Transfert :

Founded in 2000, Inserm Transfert SA is the private subsidiary of the French National Institute of the Health and Medical Research (Inserm), dedicated to technology transfer (from invention disclosure to industrial partnership) and strategic partnerships. Since 2009, Inserm Transfert has run a proof of concept fund. Inserm Transfert also manages European and International research projects, supports large scale projects in epidemiology and public health. The company is also committed to seed financing in the biotech sector, through its dedicated seed fund company Inserm Transfert Initiative. www.inserm-transfert.fr

About TRI :

Translational Research Informatics Center of Foundation for Biomedical Research and Innovation was founded in 2003 by the Japanese Ministry of Education, Sports, Science and Technology (MEXT) and Kobe City, as the first academic data center and statistical analysis center for clinical studies in Japan. TRI is available for all medical researchers who conduct clinical studies by providing comprehensive support from research planning to data analysis. More than 200 clinical research and trials have been supported by TRI. TRI contributes to the improvement of public health through innovation of technology, consolidation of infrastructure, and creation of new science. <http://www.tri-kobe.org>

Press Contacts	
Inserm Transfert	Foundation for Biomedical Research and Innovation, Translational Research Informatics Center
Céline Cortot communication@inserm-transfert.fr +33 1 55 03 01 68	Tsutomu Nishimura t-nishimura@tri-kobe.org +81 78 303 9108